[1] 陈雨, 张文. 解读首个《IgG4相关性疾病管理和治疗的国际共识指南》[J]. 中华临床免疫和变态反应杂志, 2015, 9(03): 159-162.
[2] Kamisawa T, Funata N, Hayashi Y, et al. Close relationship between autoimmune pancreatitis and multifocal fibrosclerosis[J]. Gut, 2003, 52(5): 683-687.
[3] Mattoo H, Mahajan V S, Maehara T, et al. Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease[J]. J Allergy Clin Immunol, 2016, 138(3): 825-838.
[4] Della-Torre E, Bozzalla-Cassione E, Sciorati C, et al. A CD8α- subset of CD4+SLAMF7+ cytotoxic t cells is expanded in patients with IgG4-related disease and decreases following glucocorticoid treatment[J]. Arthritis Rheumatol, 2018, 70(7): 1133-1143.
[5] 刘铮, 彭琳一. IgG4相关性疾病发病机制[J]. 中华临床免疫和变态反应杂志, 2019, 13(6): 454-457.
[6] Ardila-Suarez O, Abril A, Gómez-Puerta J A. IgG4-related disease: a concise review of the current literature[J]. Reumatol Clin, 2017, 13(3): 160-166.
[7] Sato Y, Kojima M, Takata K, et al. Multicentric Castleman's disease with abundant IgG4-positive cells: a clinical and pathological analysis of six cases[J]. J Clin Pathol, 2010, 63(12): 1084-1089.
[8] Umehara H, Okazaki K, Masaki Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011[J]. Mod Rheumatol, 2012, 22(1): 21-30.
[9] Sah R P, Pannala R, Chari S T, et al. Prevalence, diagnosis, and profile of autoimmune pancreatitis presenting with features of acute or chronic pancreatitis[J]. Clin Gastroenterol Hepatol, 2010, 8(1): 91-96.
[10] Wang Q, Zhang X, Zhang F. Autoimmune pancreatitis: current concepts[J]. Sci China Life Sci, 2013, 56(3): 246-253.
[11] Stone J H, Khosroshahi A, Deshpande V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations[J]. Arthritis Rheum, 2012, 64(10): 3061-3067.
[12] Shimosegawa T, Chari S T, Frulloni L, et al. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology[J]. Pancreas, 2011, 40(3): 352-358.
[13] Goyal S, Sakhuja P. Autoimmune pancreatitis: current perspectives[J]. Indian J Pathol Microbiol, 2021, 64(Supplement): S149-S159.
[14] Kozoriz M G, Chandler T M, Patel R, et al. Pancreatic and extrapancreatic features in autoimmune pancreatitis[J]. Can Assoc Radiol J, 2015, 66(3): 252-258.
[15] Hegade V S, Sheridan M B, Huggett M T. Diagnosis and management of IgG4-related disease[J]. Frontline Gastroenterol, 2019, 10(3): 275-283.
[16] Nakazawa T, Shimizu S, Naitoh I. IgG4-related sclerosing cholangitis[J]. Semin Liver Dis, 2016, 36(3): 216-228.
[17] Tanaka A. IgG4-related sclerosing cholangitis and primary sclerosing cholangitis[J]. Gut Liver, 2019, 13(3): 300-307.
[18] Minh Thong P, Dang Luu V, Tra My T T, et al. IgG4-related sclerosing cholangitis mimicking cholangiocarcinoma[J]. Case Rep Oncol, 2021, 14(1): 39-46.
[19] Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4 related disease[J]. BMJ, 2020, 369: m1067.
[20] Kamisawa T, Zen Y, Pillai S, et al. IgG4-related disease[J]. Lancet, 2015, 385(9976): 1460-1471.
[21] Okazaki K, Chari S T, Frulloni L, et al. International consensus for the treatment of autoimmune pancreatitis[J]. Pancreatology, 2017, 17(1): 1-6.
[22] Khosroshahi A, Wallace Z S, Crowe J L, et al. International consensus guidance statement on the management and treatment of IgG4-related disease[J]. Arthritis Rheumatol, 2015, 67(7): 1688-1699.
[23] 闵赛南, 吴立玲, 俞光岩, 等. IgG4相关性疾病发病机制的研究进展[J]. 中国病理生理杂志, 2019, 35: 2290-2298.
[24] Wallace Z S, Zhang Y, Perugino C A, et al. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts[J]. Ann Rheum Dis, 2019, 78(3): 406-412. |
